University of Arizona Develops Promising ALS Drug, XL20, Showing Positive Results
Researchers at the University of Arizona have developed an experimental drug, XL20, which shows promise in slowing the progression of ALS, a neurodegenerative disease. The drug targets a specific region of the TDP-43 protein, which is implicated in nearly all ALS cases. By binding to this region, XL20 reduces nerve cell death without affecting the protein's normal function. In animal studies, the drug extended survival and reduced muscle weakness, while in human cell tests, it reversed some disease-like damage. This approach may also benefit other TDP-43-linked dementias, including certain Alzheimer's cases. 
